Meeting Newsroom

FDA Grants Approval to Daratumumab and Hyaluronidase for High-Risk Smoldering MM
On November 6, 2025, the FDA granted approval to daratumumab and hyaluronidase-fihj for the treatment of patients with high-risk smoldering multiple myeloma.
FDA Grants Approval to Belantamab Mafodotin for Patients With R/R MM
The FDA approved belantamab mafodotin with bortezomib and dexamethasone treatment for patients with R/R multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
Back to top